Drug Pipeline & Clinical Insights – November 2026
Explore recent approvals for HIBSAGO and Juvmo, with LucyRx clinical insights on treatment eligibility, safety monitoring, and pharmacy benefit costs.
Explore recent approvals for HIBSAGO and Juvmo, with LucyRx clinical insights on treatment eligibility, safety monitoring, and pharmacy benefit costs.
TPAs are being asked to help employers make sense of more pharmacy benefit options, but they do not need to take on PBM integration work. This article explains how clear responsibilities, useful data, and an accountable PBM partnership can strengthen client service.
This month’s Drug Pipeline & Clinical Insights explores three new specialty therapies and what they could mean for pharmacy benefits, including cost, access, and appropriate use.
Employers need to know whether a pharmacy savings figure represents an opportunity or an actual result. This article explains how to evaluate savings methodology, assumptions, and outcomes.
Pharmacy savings shouldn’t come at the employee’s expense. See how one large hospitality and entertainment employer reduced net pharmacy spend by 15% in year one while lowering member PMPM from $16.10 to $9.52, through focused GLP-1 management, Care Guide support, and a smart biosimilar strategy.
Pharmacy access is the first outcome of a pharmacy benefit. When employees can’t reach their medication, adherence, productivity, and trust break down quickly.